In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
|Articles|July 25, 2011
Reynaldo Garcia on CML BCR-ABL Testing
Author(s)Reynaldo Garcia, RN, OCN
Reynaldo Garcia From Lineberger Comprehensive Cancer Center on CML BCR-ABL Testing Recommendation
Advertisement
Reynaldo Garcia, RN, OCN®, Lineberger Comprehensive Cancer Center—Protocol Office, University of North Carolina at Chapel Hill on CML BCR-ABL Testing Recommendation
Advertisement
Related to this article
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.
Most oral blood cancer drug prescriptions were first rejected by insurers, and fill rates fell sharply when out-of-pocket costs topped $175.
At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Grants Accelerated Approval to Dostarlimab in dMMR Rectal Cancer
2
How AI Could Ease the Cost Crisis in Cancer Care
3
Anktiva Plus BCG: 84% of Responders Cystectomy-Free at 3 Years
4
Automated Breast Ultrasound Tied to Fewer False-Positives in Dense Breasts
5